RGNX is tracked by BiotechSign with a current catalyst score of 66/100 and grade B. The page summarizes 0 active signals, including 0 PDUFA, 0 insider buying, and 0 clinical trial signals, with data refreshed on 2026-07-19.
As of 2026-07-19, REGENXBIO Inc (RGNX) has a BiotechSign Catalyst Score of 66/100, rated B. The company has 0 active signals tracked by BiotechSign. BiotechSign scores combine FDA pipeline data, clinical trial activity, SEC insider filings, dilution risk, and sentiment analysis into a single catalyst grade.
This data is for informational purposes only and does not constitute financial or medical advice. Biotech and pharmaceutical stocks carry extreme risk, including binary FDA outcomes that can result in total loss. Always conduct your own due diligence. Source: BiotechSigns (biotechsign.com).
REGENXBIO Inc (RGNX) is the lead sponsor of 5 active clinical trials listed on ClinicalTrials.gov[3], including 2 Phase 3[1], 2 Phase 2[2].
Trial NCT05693142[4] evaluates RGX-202 in Duchenne Muscular Dystrophy with a target enrollment of 65 participants. Trial NCT03566043[5] evaluates RGX-121 in Mucopolysaccharidosis Type II (MPS II) with a target enrollment of 48 participants.
RGNX has 1 Form 4 insider filing recorded at the SEC in the past 30 days[6].